Chronic heart disease patients whose lives are at risk could soon be prescribed a newly approved drug.
Patients with chronic heart failure and left ventricular systolic dysfunction could soon be given Inspra (Eplerenone) as well as standard therapy.
Pfizer announced that the drug had been approved for use with these patients, although it has already been used in the UK to treat certain patients for some time.
Heart disease kills approximately 94,000 people in the UK every year, while 2.6 million Britons are sufferers.
Some 875,000 of those people have to be admitted to hospital regularly, and their life expectancy is dramatically reduced as a result of their condition. Each hospital stay typically lasts 11 days, which adds to the costs of the NHS.
The Royal Brompton Hospital’s professor Martin Cowie said: “These admissions account for most of the costs of treating chronic heart failure. New strategies with the potential to reduce these costs as well as extending patients’ lives are particularly welcome.”